United States-based PDL BioPharma Inc (NASDAQ: PDLI) has reported its financial results for 12 months ended 31 December 2018.
The company reported total revenues of USD198.1m for 2018.
The firm posted a GAAP net loss of USD68.9m or USD0.47 per share for 2018.
The company repurchased 8.7 million shares of common stock in the open market during the fourth quarter of 2018 at an average price of USD2.94 per share, or USD25.5m.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development